Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: teevee	6/8/2007 9:43:36 AM
	of 631

April 26, 2006 The deal gives Isotechnika (TSX:ISA) the option to obtain an exclusive license to use Cellgate Inc.'s patented transporter technology to deliver ISA247 in topical form to patients. Clinical trials have shown the drug is effective in treating moderate to severe psoriasis. Successful studies using Cellgate's technology would allow it to be prescribed for the broader group with mild to moderate condition. Isotechnika will pay Cellgate $500,000 US for the studies, which are expected to last a year. Isotechnika CEO Randall Yatscoff said the development of a topically administered ISA247 product will allow them to optimize the market potential by making it available for mild to severe psoriasis cases. Cellgate chairman Linda Sonntag said they expect their technology will safely expand ISA247's use to the 65 per cent of patients with mild psoriasis, and supplement those with moderate to severe psoriasis. ISA247 is an immunosuppressant currently in a Phase III clinical trial extension for the treatment of moderate to severe psoriasis. It has also sucessfully completed a Phase IIa trial for kidney transplantation. The company has another immunosuppressive compound, TAFA93, in the pipeline.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next